The risk of transmission of blood-borne pathogens by transfusion is a persistent problem in medicine. To address this safety issue, INACTINE™ PEN110 chemistry is being utilized to develop a process for preparing pathogen-reduced red blood cell concentrates (RBCC). The purpose of this study was to characterize the virucidal effectiveness of the INACTINE™ PEN110 chemistry in full units of RBCC by using a panel of viruses with diverse properties in composition, size and shape.
Introduction
Viruses known to contaminate cellular blood products comprise a wide range of physicochemical characteristics, including the presence or absence of a lipid envelope. Non-enveloped viruses contaminating cellular blood products include, but are not limited to, parvovirus B19V, TT virus (TTV) and SEN-V viruses. Current estimates of the risk of infection per 10 million donations in the United States for viruses for which routine testing has been implemented are 13-14 for human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2), 16 for human T-cell lymphotrophic virus types 1 and 2 (HTLV-1 and HTLV-2), 66-153 for hepatitis B virus (HBV) and 16-32 for hepatitis C virus (HCV) [1] [2] [3] . The risk of transfusion-transmitted infections per 1000 donations in the United States for viruses that contaminate the blood supply, but for which routine testing is not available, is 1-2 for parvovirus B19V, 40-400 for TTV, 10-20 for GBV-C/hepatitis G virus, 18 for SEN-V and 0-30 for cytomegalovirus (CMV) in leucoreduced blood [4] [5] [6] [7] [8] [9] [10] [11] . It was shown recently that 19 in 880 plasma minipools (95 plasma units per pool) were contaminated with enteroviruses of the A and B group, which include coxsackieviruses and echoviruses [12] . It is clearly impractical to implement routine screening tests for the second group of viruses because of the large number of viruses and their high frequency in blood. It is also recognized that the blood supply is vulnerable to the emergence of new pathogens. Therefore, the development of a safe and effective pathogen-reduction technology will represent an important advancement in the transfusion safety of RBCC.
A successful pathogen-reduction technology must be robust and have a wide spectrum of pathogen-inactivating activity to provide an appropriate safety margin against enveloped and non-enveloped viruses, bacteria and parasites, while preserving the integrity and functionality of the treated product. In addition, the safety of the treated product must not be compromised by introducing the pathogenreduction process. A virus-reduction process for RBCC has been developed using the INACTINE ™ PEN110 chemistry [13] . PEN110, a proprietary chemical-inactivating agent, is a highly water-soluble, low-molecular-weight electrophilic compound. The reactive centre of the molecule is an aziridino group, which alkylates nucleophiles when protonated. The aziridino group of PEN110 has been chemically modified to provide stability and enhanced preference for nucleic acids. The selectivity of PEN110 for nucleophilic centres of nucleic acids is attributed to a proposed three-step mechanism of action [14] . PEN110 covalently interacts with nucleophilic centres of nucleic acids, predominantly with N7 of guanine residues. Alkylation of position N7 by PEN110 can result in spontaneous opening of the guanine imidazole ring [15] , producing a modified base that acts as a potent stop signal for polymerases [16] . Base modification can also produce abasic sites, representing a stop signal for DNA and RNA polymerases [17, 18] . The abasic site is a chemically unstable structure and its formation can lead to spontaneous strand breakage [19] . Strand breakage in the absence of repair usually results in the disruption of transcription and replication of the genomes [20] . Recent studies to demonstrate the mechanism of action of PEN110 show that a polymerase was unable to produce full-length copies of PEN110-treated phage M13 DNA templates [21] . DNA replication was predominantly aborted at guanine residues, indicating covalent modification of these bases. The disruption of nucleic acid replication forms the biochemical basis for pathogen reduction by the INACTINE ™ PEN110 process.
The first step in the process is the addition of PEN110 to leucoreduced RBCC to a final concentration of 0·1% vol/vol PEN110. Next, the PEN110-RBCC mixture is incubated for 18-24 h at 22 ± 2 ° C. The third step of the process is the removal of PEN110 to a non-toxic level using an automated cell-washing process. At the end of the washing process, the red cells are ready for cold storage or for transfusion. For the virus-inactivation studies, the red cells were not washed, instead the PEN110 reaction was chemically quenched. The results of a Phase II clinical trial using this process have been recently reported [22] .
To demonstrate the robustness and broad virucidal spectrum of the INACTINE ™ technology, we evaluated the kinetics of PEN110 virus reduction in leucoreduced RBCC units using a panel of 11 viruses that included models for B19V, hepatitis E/Norwalk viruses, HCV, human herpesviruses and cellassociated HIV. The robustness of the PEN110-reduction process was also demonstrated by comparing the kinetics of virus reduction in RBCC prepared in CPD/AS-1, CP2D/AS-3 and CPD/AS-5 solutions, which are approved for storage of RBCC in the USA. To further measure the true effect and the robustness of PEN110 on virus reduction, preliminary studies were performed to determine potential cytotoxicity of the PEN110-treated RBCC to the indicator cells and the potential interference with the ability of the virus to infect the indicator cells, resulting in either an underestimation or overestimation of the virus-reduction factors [23] . 
Materials and methods

Viruses, cells and reagents
RBCC preparation
Citrate-phosphate-dextrose (CPD)-collected RBCC units stored in AS-1 were obtained from Oklahoma Blood Institute (Oklahoma City, OK), CP2D-collected RBCC units stored in AS-3 from Tennessee Blood Services (Memphis, TN), and CPD-collected RBCC units stored in AS-5 from Central Indiana Regional Blood Center (Indianapolis, IN). RBCC were leucoreduced using an RCXL High Efficiency Leukocyte Removal Filter System (Pall Biomedical, Inc., Fajardo, Puerto Rico) prior to performing inactivation studies. Leucoreduced RBCC were used for these studies to enable measurement of the true effect of PEN110 on virus inactivation and to avoid possible interaction of the white blood cells with the virus, resulting in interference with the infectivity assay and overestimation of the virus kill. The haematocrit for each unit was adjusted to 60-70%, which is at the upper range of standard levels of 55-65% for RBCC units. The RBCC units were stored for up to 7 days at 4 ° C prior to use.
PEN110 treatment
Leucoreduced RBCC units CPD/AS-1, CP2D/AS-3 and CPD/ AS-5 were spiked separately with approximately 10% (vol/ vol) of each virus stock and then equilibrated for 1 h at room temperature. PEN110 was added to the virus-spiked RBCC units to a final concentration of 0·1% (vol/vol) and incubated at 22 ± 2 ° C for up to 22 ± 2 h. At specified time-points, a sample was taken from the treated unit and the PEN110 reaction stopped by the addition of 1 M sodium thiosulphate (STS)/1 M 3-morpholinopropanesulphonic acid (MOPS) buffer to a final concentration of 100 m M each for 1 h at 22 ± 2 ° C. As reactions were stopped chemically rather than by cell washing, the virucidal effect of PEN110 treatment alone was determined.
Infectivity assays
The virus titres of the treated samples and controls were determined using TCID 50 or PFU assays.
TCID 50 assay
Samples were diluted threefold in defined medium and 200-µ l aliquots were plated onto their respective indicator cells in replicates of eight wells per dilution in 24-well plates. After 24 h of incubation at 37 ± 2 ° C in a 5% CO 2 incubator to increase virus adsorption to indicator cells, the cell monolayer was washed with dextrose gelatin veronal (DGV) buffer (Biowhittaker, Walkersville, MD) to remove residual RBCC and replaced with complete growth medium. In some cases, i.e. PPV, the supernatant from wells was subcultured onto fresh monolayers 6-7 days postinfection to increase the sensitivity of the infection assay. In the case of FMDV, VESV and BTV, the samples were diluted 10-fold in defined medium and 100-µ l aliquots were plated onto their respective indicator cells in replicates of eight wells per dilution in 96-well plates. The cytopathic effect (CPE) for each dilution was determined and used to calculate the titres by the SpearmanKarber method [28] . The titres were expressed as log 10 TCID 50 /ml.
PFU assay
Serial 10-fold dilutions of the sample were performed in defined medium, and 600-µ l aliquots were inoculated onto respective indicator cells in replicates of two or four wells per dilution in a six-well plate. The plates were incubated at 37 ± 2 ° C for 3 h followed by washing with DGV to remove RBC. The plates were overlaid with 0·8% Seakem agarose (Biowhittaker) prepared in MEM containing 1% FBS. After solidification of the overlay, the plates were incubated at 37 ± 2 ° C and fed with liquid maintenance media every 3-5 days until plaques appeared. The plates were stained with 0·01% neutral red (Sigma, St. Louis, MO) prepared in the respective maintenance media and incubated overnight at 37 ± 2 ° C. Following removal of the neutral red stain, wells containing 5-50 plaques were used to calculate the titre as log 10 PFU/ml [28] .
Cell-associated HIV assay
Leucoreduced CPD/AS-1 RBCC were spiked with 10% of (vol/vol) U1 cells resuspended in RPMI 1640 to a final concentration of 1 × 10 7 cells/ml, which corresponds to the approximate leucocyte concentration in whole blood. The U1-spiked RBCC were treated with PEN110 to a final concentration of 0·1% (vol/vol) and incubated at 22 ± 2 ° C for up to 22 ± 2 h. At specified time-points, a sample was collected and the U1 cells were isolated by Ficoll-Paque density centrifugation (AP Biotech, Piscataway, NJ), with PEN110 removed by washing the U1 cells three times with PBS. The virus titres were determined by diluting samples and controls 10-fold in RPMI 1640 containing 100 ng/ml phorbol 12-myristate 13-acetate (PMA; Sigma) and plating onto HeLa-CD4 + cells in replicas of four wells/dilution in 24-well plates.
After 24 h of incubation at 37 ± 2 ° C to allow for induction of HIV expression, the PMA-containing medium was replaced with complete growth medium consisting of RPMI 1640 and 10% FBS. After 3 days at 37 ± 2 ° C, the indicator cells were fixed and permeabilized with 100% methanol (Sigma), and immunolabelled with a primary HIV immune globulin (New York Blood Center, New York, NY) and a secondary horseradish peroxidase-conjugated anti-human IgG (ICN Biomedicals, Costa Mesa, CA). Antibody-labelled cells were then stained by incubation with a substrate solution containing 3-amino-9-ethylcarbazole, dimethylformamide, hydrogen peroxide and sodium acetate-acetic acid buffer (all reagents purchased from Sigma). The number of foci or PFU was counted and used to calculate titres expressed as log 10 PFU/ml.
Cytotoxicity and interference studies
As recommended by the Committee for Proprietary Medicinal Products (CPMP) guidelines, preliminary studies were performed to determine potential cytotoxicity of the samples to the indicator cells and potential interference with the ability of the virus to infect the indicator cells, resulting in either an underestimation or overestimation of the virus-reduction factors [23, 29, 30] .
Cytotoxicity studies
To investigate the potential combined cytotoxic effect of RBCC, PEN110 and chemical quenching, the test article for cytotoxicity assessment was produced by mimicking the INACTIN ™ PEN110 pathogen-reduction process in the absence of virus. RBCC were 'mock spiked' with defined culture media to mimic virus addition, treated with a final concentration of 0·1% (vol/vol) PEN110 and incubated at 22 ± 2 ° C for 22 ± 2 h. The PEN110 reaction was stopped by the addition of 1 M STS/1 M MOPS to a final concentration of 100 m M for 1 h at 22 ± 2 ° C. The treated RBCC was diluted threefold to 1 : 81 in defined culture media to determine the dilution at which the test sample does not exert a cytotoxic effect on the indicator cells. After incubation with the indicator cells at 37 ± 2 ° C for 22 ± 2 h, the samples were removed from the wells and the cell monolayer washed with DGV buffer and replaced with complete medium. Cytotoxicity was measured 24 h postwash and expressed as the percentage reduction in confluence of cell monolayer in comparison to the confluence of the cell monolayer of the media controls. A sample dilution was considered noncytotoxic when the cell confluence on the treated sample was within ± 20% compared to the confluence of the cell monolayer media control.
Interference studies
A modified version of the PEN110 virus-inactivation studies was used to evaluate the potential interference of RBCC and PEN110 under worst-case conditions for the ability of low titres of virus to infect indicator cells. PEN110 was added to the RBCC to a final concentration of 0·1% (vol/vol) in the absence of virus spike and incubated for 1 h at 22 ± 2 ° C. , 10 0 and 10 − 0·5 log 10 TCID 50 / ml. The virus-spiked, quenched PEN110-treated RBCC was then incubated for 22 ± 2 h at 22 ± 2 ° C to mimic the treatment period. Each sample was then inoculated onto indicator cells in replicates of eight in a 24-well plate and incubated for 24 h for virus adsorption. The different virus concentrations were also spiked into defined medium and plated along with PEN110-treated RBCC to serve as a positive control. After 24 h of incubation at 37 ° C ± 2 ° C, the sample was removed and the cell monolayers washed with DGV buffer and replaced with complete medium for the remainder of the infectivity assay. Virus titres were calculated for the PEN110-treated RBCC samples and compared to the media-spiked controls. A dilution was considered non-interfering when the titre was ± 0·5 log 10 TCID 50 /ml compared to the media control.
Statistical analysis
In virus titrations, the titre was expressed in statistical units as log 10 TCID 50 , using the Spearman-Karber formula or as a log 10 PFU/ml [28] . The 95% confidence level for the calculation of the theoretical minimal detectable (TMD) virus particle concentration is routinely used as a safety factor and is chosen to provide a balance between the need to provide a realistic safety margin and the need to keep the TMD titre as low as possible to maximize the virus-clearance factors. The probability that an aliquot does not contain infectious viruses is calculated by rearranging the following formula: P = e −cv to c = log e P/−v, where c is the concentration of infectious particles per litre and v is the sample volume (in litres) to be assayed. Virus-reduction factors were calculated, taking into consideration the lowest dilution at which cytotoxicity and interference were not detected, as well as the TMD virus concentration [31] .
Results
PEN110 reduction kinetics of enveloped and nonenveloped viruses in RBCC units
The kinetics of PEN110 reduction of four enveloped viruses (BVDV, PRV, VSIV and SIN), and six non-enveloped viruses (PPV, Reo-3, Adeno-2, VESV, BTV and FMDV) were demonstrated in single units of leucoreduced RBCC units treated with 0·1% (vol/vol) PEN110 at 22 ± 2 °C for up to 22 ± 2 h. The kinetics of virus reduction was determined by collecting samples at 3, 6, 12, 18 and 22 h post-treatment and assaying for residual virus. The results of these studies showed that PEN110 treatment effectively reduced SIN, VSIV, VESV, FMDV and BTV to the limit of detection of the assay within the first 3 h of treatment with a reduction factor greater than 5·4-7·5 log 10 TCID 50 /ml (Figs 1a, 1b, 2d, 2e, 2f ; Tables 1 and  2 ). BVDV and PRV were reduced to the limit of detection of the assay within the first 12 h of treatment with reduction factors of 5·9 and 6·3 log 10 TCID 50 /ml, respectively (Fig. 1c,  1d ; Table 1 ).
The results also showed that PEN110 treatment effectively reduced PPV to the limit of detection of the assay for a reduction factor of > 6·2 log 10 TCID 50 /ml within 18 h of treatment ( Fig. 2a; Table 2 ). Adeno-2 and Reo-3 viruses were also reduced to the limit of detection of the assay for reduction factors greater than 5·3 and 5·6 log 10 PFU/ml, respectively, within 18 h of treatment. (Fig. 2b, 2c ; Table 2 ). The kinetics and the rate of PEN110 inactivation of BVDV, PRV, VSIV, SIN, PPV, Reo-3 and Adeno-2 spiked in CPD/AS-1, CP2D/AS-3 and CPD/AS-5 RBCC units were comparable, indicating that the collection system employed did not affect the inactivation of virus by PEN110 treatment (Fig. 1a−1d and Fig. 2a−  2c ; Tables 1 and 2 ). These results clearly indicate that the 
(a) Inactivation kinetics of sindbis (SIN) virus. (b) Inactivation kinetics of vesicular stomatitis Indiana virus (VSIV). (c) Inactivation kinetics of bovine viral diarrhoea virus (BVDV). (d) Inactivation kinetics of pseudorabies virus (PRV).
composition of the storage solution does not impact the virucidal effectiveness of PEN110.
The virucidal effect of PEN110 was further demonstrated by treating leucoreduced RBCC spiked with U1 cells, which contain two copies of proviral HIV per cell, to a final concentration corresponding to the number of leucocytes generally present in whole blood. PEN110 reduced the infectivity of U1-associated HIV to the limit of detection of the assay within 6 h of treatment, resulting in reduction factors of ≥ 4·2 log 10 PFU/ml (Fig. 3) .
The cytotoxicity on indicator cells of PEN110-treated RBCC quenched with 1 M STS/1 M MOPS was determined for PT-1, A-549, l-929, BT, PK-13 and Vero cells. The undiluted sample was considered cytotoxic, with most of the cell monolayer damaged or unreadable as a result of the high concentration of RBCC. The lowest non-cytotoxic dilution under the assay conditions previously described was 1 : 3 for all cell lines, resulting in a starting dilution of 1 : 3, or the equivalent of 0·48 log 10 TCID 50 /ml (Table 3) . 
Each collection system (CPD/AS-1, CP2D/AS-3 and CPD/AS-5) was tested in duplicate. 
Table 1 PEN110 kinetics of inactivation of enveloped viruses in CPD/AS-1, CP2D/AS-3 or CPD/AS-5 red blood cell concentrate (RBCC) units
Interference studies showed that PEN110-treated RBCC quenched with 1 M STS/1 M MOPS interfered with the ability of BVDV and PPV to infect the cell monolayer in the undiluted sample. A sample was considered non-interfering when the titre was ± 0·5 log 10 TCID 50 /ml compared to the media control. Therefore, the lowest non-interfering dilution for PPV and BVDV was found to be 1 : 3, resulting in a starting dilution of 1 : 3, or the equivalent of 0·48 log 10 TCID 50 /ml (Tables 4 and 5 ). Interference studies were not performed for the other viruses. The results from the cytotoxicity and interference studies, as well as the 95% confidence level for the TMD virus particles, were taken into consideration for calculating the virus-reduction factors.
The lowest non-cytotoxic and interfering dilution for all infectivity assay systems was 1 : 3, therefore 0·48 log 10 TCID 50 /ml was added to the calculated TMD for each assay system to determine the limit of detection for each assay.
Discussion
The results from this study establish that the process for virus reduction with INACTINE™ PEN110 chemistry is robust and inactivates a wide spectrum of viruses under conditions that preserve the quality of RBC. One measure of the robustness of the virus-reduction technology is the breadth of viruses inactivated under the same reaction conditions. The broad range of virucidal activity of PEN110 was demonstrated using a panel of viruses that included BVDV, PRV, VSIV, SIN, PPV, Reo-3, Adeno-2, VESV, BTV, FMDV and cell-associated HIV. These viruses collectively encompass a wide range of physicochemical characteristics, including structure and biochemical composition (enveloped or non-enveloped, DNA or RNA), size (5, to > 200-kb genome and 20-200-nm particle size) and cell-free or cell-associated viruses. BVDV, PRV and 7·15  0·00  6·43  0·00  5·9  0·00  8·25  0·00  7·6  0·00  7·19  0·00  3  3·12  4·03  4·53  1·90  4·8 
Titre and reduction factor expressed as log 10 tissue culture infective dose 50% (TCID 50 )/ml. Titre and reduction factor expressed as log 10 plaque-forming units/ml. PPV are recognized as models of HCV, herpesvirus and B19V, respectively [31] . VESV, a calicivirus, is recognized as a model of hepatitis E virus and Norwalk virus. SIN, VSIV, Reo-3, Adeno-2, BTV and FMDV were used to further assess the wide spectrum of virucidal activity of the PEN110 RBCC pathogenreduction process. PEN110 was extremely effective at inactivating HIV-infected U1 cells, a model of cell-associated HIV and other cell-associated viruses, such as HTLV-1/2, CMV and Epstein-Barr virus, which are predominantly transmitted through cellular components. Inactivation of HIV-infected U1 cells is in agreement with previous studies showing that PEN110 treatment functionally inactivates PBMC present in RBCC [32] . A second measure of robustness was to determine the significance of varying the RBCC composition on the virucidal activity. The kinetics and the rate of PEN110 reduction of BVDV, PRV, SIN, VSIV, Adeno-2, Reo-3 and PPV spiked into CPD/AS-1, CP2D/AS-3 and CPD/AS-5 RBCC units were comparable in all three storage solutions, indicating that the collection system employed did not affect the efficacy of PEN110 treatment (Fig. 1a−1d and Fig. 2a−2c) . The similar kinetics of PEN110 reduction for all these viruses clearly indicate that the INACTINE™ PEN110 RBC pathogen-reduction process is very robust and can be used in RBCC collected in any of these approved storage solutions. RBCC and PEN110-treated RBCC are cytotoxic to indicator cells. The degree of cytotoxicity is innate to each cell line. Like many other test articles, red blood cells also have the potential to bind viruses, resulting in interference with the treatment or the ability of the virus to infect the indicator cells (data not shown). The cytotoxicity to indicator cells can result in an underestimation of the virus kill when indistinguishable from the virus CPE. Interference, on the other hand, can result in overestimation of virus kill when lack of virus infectivity as a result of interference is attributed to the treatment. To reduce the combined effect of cytotoxicity and interference for PEN110-treated RBC, the in vitro infectivity assay was modified to include incubation of the PEN110-treated samples with the indicator cells for 24 h and removal of the PEN110-treated RBCC and controls. The longer adsorption step allows for transfer of the virus to the indicator cells, whereas the removal and washing steps reduce the cytotoxic effect of the sample to the indicator cells. Cytotoxicity and interference studies under the described conditions determined that only the undiluted PEN110-treated RBCC test sample exerted an inhibitory effect on the ability of all assay systems to accurately monitor viral infection. When the test sample was diluted 1 : 3 in defined media, all infectivity assays were able to produce infectivity results comparable to the media controls, resulting in a starting dilution of 1 : 3, or 0·48 log 10 TCID 50 /ml. The 95% confidence level for the TMD virus particles and the starting dilution, based on the cytotoxicity and interference results, were combined to determine the limit of detection of each infectivity assay.
A detailed examination of the kinetics of inactivation of this panel of viruses showed differences in the rate of virus inactivation. In general, the rate of inactivation was not dependent upon whether a virus was enveloped or nonenveloped. For example, some non-enveloped viruses (such as VESV, BTV and FMDV) were inactivated faster than some enveloped viruses (such as PRV and BVDV). In contrast, the non-enveloped virus, PPV, was slower to inactivate than BVDV. The kinetics of inactivation for these two viruses was characterized by a fast initial phase followed by a slower phase (Fig. 1c, Fig. 2a ). Reduction factors of 4·5 and 4·0 log 10 TCID 50 /ml were achieved for BVDV and PPV in the first 3 h of treatment and to the limit of detection of the assay within the first 12 and 18 h of treatment, respectively. The kinetics of inactivation for PRV, Reo-3 and Adeno-2 are linear, with PRV inactivated to the limit of detection within the first 12 h, and Reo-3 and Adeno-2 within 18 h of treatment ( Fig. 1d; Fig. 2b, 2c) .
The clinical relevance of the virucidal effect of PEN110 was assessed by comparing published viral loads of HCV, B19V, cell-associated HIV and CMV, with BVDV, PPV and U1 infectivity reduction shown experimentally in this study. The HCV load during the preseroconversion phase generally ranges from 10 5 to 10 7 genome equivalents/ml (geq/ml) of plasma [2] . The HCV infectious dose for humans is unknown. However, chimpanzee transmission data, which are consistent with observations in humans, show that an infectious dose equivalent to 10 copies of HCV genome is sufficient to infect chimpanzees [2] . Therefore, 10 7 geq/ml, the approximate maximum HCV load in plasma during the preseroconversion phase, corresponds to 10 6 infectious doses/ml, which is comparable to the viral reduction factor achieved for BVDV (≥ 5·90 log 10 TCID 50 /ml) with this process. The parvovirus B19V load in human plasma ranges from less than 10 2 −10 11 geq/ml, with approximately 75% of the NAT-positive donations containing less than 10 7 geq/ml [33] . As with BVDV, the viral infectivity reduction factor achieved with PPV (≥ 6·2 log 10 TCID 50 /ml) is expected to reduce significantly (or even eliminate) B19V virus transmission in PEN110-treated RBC Furthermore, a separate study has shown that PEN110 effectively reduces cell-free HIV to the limit of detection of the infectivity assay within 12 h of treatment for a mean reduction factor of ≥ 4·47 log 10 TCID 50 /ml [37] . The cell-free HIV plasma load in infected individuals ranges between 2 and 7 log 10 geq/ml [38, 39] . The ratio of geq/ml to human infectious dose may be ≥ 1000 [40] . The peak infectious titre for cell-free HIV may thus be 4 log 10 TCID 50 /ml, which corresponds to the experimentally inactivated cell-free HIV loads. Together, this demonstrates that PEN110 exhibits a clinically relevant virucidal efficacy.
The efficacy of the PEN110 compound against nonenveloped viruses such as PPV, Adeno-2 and Reo-3 could be, in part, attributed to its mechanism of action and to the physical-chemical characteristic of the molecule. The mechanism of the PEN110 action includes initial ionic binding of positively charged PEN110 to negatively charged phosphate groups, in situ self-activation of the aziridino group by protonation followed by covalent modification of nucleophilic groups of RNA or DNA. This mechanism of action is dependent on temperature and incubation time during treatment, structural composition of the viruses and, importantly, characteristics of the reagent such as molecule size, charge, water solubility, rate of penetration and enhanced specificity for nucleic acid targets. Based on the characteristics of PEN110, the RBC pathogen-reduction process has been optimized to include treatment of single RBCC units with 0·1% (vol/vol) PEN110 at 22 ± 2 °C for up to 22 ± 2 h. Thus, these optimized conditions of PEN110 treatment provide a robust pathogen-reduction process that includes viruses, bacteria and parasites, while preserving the integrity, mechanical and physiological functionality of the RBC, as demonstrated by in vitro studies and the results of a Phase II clinical trial using this process [22] .
In summary, treatment of RBCC with PEN110 was shown to be an effective and robust method of virus reduction. The PEN110 RBC pathogen-reduction process has a wider spectrum of virucidal activity than any other known virucidal process for cellular blood products. Furthermore, previous studies have shown that the INACTINE™ PEN110 pathogen-reduction process prevents the outgrowth of deliberately inoculated blood with bacteria [41] . The process is also highly efficient at inactivating parasites such Plasmosium spp. (responsible for malaria), Trypanosome cruzi and babesia (data not shown). Importantly, the wide range of pathogenic activity of PEN110 was achieved under the same conditions in red cell physiology studies, demonstrating that the quality of the red cell is maintained [22] . The efficiency of virus reduction observed for a diverse panel of viruses strongly suggests that the process will be effective at improving the safety of the blood supply against known and unknown viruses that currently contaminate the blood supply and against emerging viruses entering the blood supply.
